#LigaChem Biosciences 141080 | Stock channels

LigaChem Biosciences141080

₩69,100-5.73%Close Oct 12

This is the start of #LigaChem Biosciences

Talk about LigaChem Biosciences here. Pull up price, chart, news and filings just for you from the message box, or mention @InverseOneBot to get an answer everyone can see.

InverseOne BotBOTOnly visible to you

Welcome to the LigaChem Biosciences channel. Here's the latest data.

리가켐바이오 141080

Close as of Oct 12

₩69,100-5.73%

Low ₩68,80052-week rangeHigh ₩225,000

At a glance: 0% of the 52-week range, estimated net outflow for 3 sessions in a row, filing check: Check first.

Disappears when you reload.

리가켐바이오 141080

Close as of Oct 12

₩69,100-5.73%

Low ₩68,80052-week rangeHigh ₩225,000

5 sessions

-19.8%

20 sessions

-22.6%

60 sessions

-42.6%

Volume

1.0x average

Price

Mar 31 ~ Oct 12

₩69,100-64.01%

Low ₩69,100High ₩206,000

Money flow

as of Oct 12

Strong outflow index-₩835.6M

Net flow, Outflow

Market flow rank: Outflow #32 of 52
Sector flow rank: #9 of 13

Multi-day trend, Persistent outflow

Cumulative flow: -₩2.5B
outflow: 3d streak

Estimated from public price, change and volume. Not actual investor net buying.

as of Oct 12

Market cap

₩2.6T

Lending balance

Little change

2,448,067 sh

KRW 0.17T

1D +0.08%5D -2.93%

New 55,861 sh, Returned 53,810 sh

Shares borrowed through securities lending that have not yet been returned. Borrowed shares are often sold afterwards, so the balance is used as a reference for pending sell pressure.

As of 2026-10-12, FSC stock lending data

Filing check

Check first2 to check first, 0 improvementschecked through Oct 14

This only counts facts confirmed in filings. It does not look at whether the price is cheap or expensive, and it is not a reason to buy or sell on its own.

Earnings quality

We read the latest periodic report and check whether profit matches cash, sales match receivables, and profit from the core business matches profit from elsewhere. There is no score, only the numbers that diverge beyond a threshold and why they matter.

2026 first half, consolidated statements, filed 2026-08-14

No numbers diverge beyond the threshold

No divergence does not mean the results are good.

Net profit and operating cash flow
Net profit -1,014억 원, operating cash flow -1,061억 원
Net profit is a loss, so no ratio is calculated.
Sales and receivables
Year on year, sales -50.8%, receivables -69.2%
Receivables 107억 원, a year earlier 347억 원
Profit from outside the core business
Pretax profit -1,023억 원, operating profit -1,094억 원, non-operating result 71억 원
Pretax result is a loss, so no share is calculated.

Source filing: 2026 first half Report a year earlier

This only checks whether the statement numbers agree with each other. It ignores the share price and is not a reason to buy or sell on its own. See the formula

Sector moves

Of 13 covered Healthcare stocks in Korean, 12 fell; the average change was -3.35%. LigaChem Biosciences moved in the same direction at -5.73%. Estimated sector flow was outflow.

Variables to watch Drug approvals and trial results, Drug pricing policy, US interest rates, USD/KRW

Risks to check A reversal after a -5.73% one-day swing, -69% below the high, the downtrend may continue, Clinical trial failure

Same-sector channels

Latest news

Stock page

Posts are members' opinions. Investment decisions and their consequences are your own.

Data: KRX daily bars, InverseOne quote snapshots, public news feeds, DART filings, InverseOne company research. Not a call to buy or sell.